Year in Review 2024 - Melanoma

Oncology 2024 Year in Review

A. van Akkooi

Year in Review 2024 - Key Updates in Melanoma Treatment

Oncology 2024 Year in Review

T. Haykal

The NADINA Trial - A Paradigm Shift in Melanoma Treatment

Oncology Data Advisor

M. Hadfield

Biomarkers for Immunotherapy in Melanoma: Where Are We Now?

Vanderbilt University Medical Center (VUMC)

D. Johnson

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

S. Patel

The Latest and Greatest in Melanoma Treatment, 2024: From Adjuvant t…

Melanoma Research Foundation

K. Margolin

Understanding TIL Cell Therapy and the Patient Journey for Advanced …

Melanoma Research Foundation

J. Lutzky

ESMO 2024 Summary: Metastatic Melanoma Highlights

2024 ESMO Annual Meeting Insights Hub

C. Blank

Medical Treatments for Melanoma: Current and Future Options

Melanoma Research Foundation

F. Collichio

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

Anti-IL-8 (BMS-986253) + Nivo + Ipi in Advanced Melanoma: Final Anal…

Matteo Simonelli

New Frontiers in Oncology: Advanced Diagnostics and Therapeutics

Springer Healthcare IME

S. Peters

Role of Nivolumab/Relatlimab in the 1L Treatment Landscape for Metas…

Rodabe Amaria

Optimal Therapy Sequence for 1L Treatment of BRAF-Mutated Metastatic…

Stanford Medicine

A. Betof Warner

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

Tarek Haykal

Optimal Treatment for BRAF-Mutated Metastatic Melanoma

Jeff Yorio

ESMO 2024 Summary: Key Metastatic and Neoadjuvant Melanoma Trials

2024 ESMO Annual Meeting Insights Hub

D. Johnson

Advances in the Treatment of Melanoma

Masterclasses in Dermatology

D. Fisher

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and R…

2024 ASCO® Annual Meeting Insights Hub

D. Johnson